Acceptable

Ideal

Target population Chronic Chronic and Acute
Geographic Distribution All regions All regions
Efficacy Non inferior to benznidazole standard dose* in all regions (parasitological) Superiority to benznidazole standard dose to different phases of disease (acute and chronic) (parasitological)
Safety Superiority to benznidazole* in the frequency of definitive treatment discontinuations for medical indication (clinical and laboratory)** Superiority to benznidazole* in the frequency of definitive treatment discontinuations for medical indication (clinical and laboratory)**
Contraindications Pregnancy No contraindications
Precautions No genotoxicity**; No pro-arrythmic potential No genotoxicity; No teratogenicity; No pro-arrythmic potential
Interactions No clinically significant interaction with anti-arrythmic and anticoagulants drugs No clinically significant interaction
Presentation Oral/Parenteral (short POC)***

Age-adapted

Oral

Age-adapted

Stability 3 years, climatic zone IV 5 years, climatic zone IV
Dosing regimen Oral – any duration

Parenteral – <7 days

<30days
Cost Lowest possible Current treatments

* As per WHO recommendation
** No genotoxicity is a condition only for NCEs
*** Need for parenteral treatment for severe disease